請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67019
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蕭斐元(Fei-Yuan Hsiao) | |
dc.contributor.author | Kai-Hsin Liao | en |
dc.contributor.author | 廖愷欣 | zh_TW |
dc.date.accessioned | 2021-06-17T01:17:25Z | - |
dc.date.available | 2022-09-08 | |
dc.date.copyright | 2017-09-08 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-08-14 | |
dc.identifier.citation | 1. The World Bank. World Health Organization Global Health Expenditure database. Health expenditure per capita. (Accessed November 30, 2016, at http://data.worldbank.org/indicator/SH.XPD.PCAP?end=2014&start=1995&view=chart.)
2. Organisation for Economic Cooperation and Development. Health at a glance: Asia/Pacific 2016. (Accessed October 05, 2016, at http://dx.doi.org/10.1787/health_glance_ap-2016-en.) 3. Ministry of Health and Welfare in Taiwan. The statistics and trends in health and welfare 2014. (Accessed March 12, 2017, 4. Organisation for Economic Cooperation and Development. Health at a glance 2015. (Accessed November 01, 2016, at http://dx.doi.org/10.1787/health_glance-2015-en.) 5. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. Journal of the National Cancer Institute 2011;103:117-28. 6. NBC News. Global cancer drug market grows to $107 Billion. (Accessed June 17, 2017, at http://www.nbcnews.com/health/cancer/global-cancer-drug-market-grows-107-billion-n584481.) 7. Hsieh CR, Sloan FA. Adoption of Pharmaceutical Innovation and the Growth of Drug Expenditure in Taiwan: Is It Cost Effective? Value in Health 2008;11:334-44. 8. Hsu JC, Lu CY. Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study. BMJ open 2016;6. 9. Garrison LP, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2009;12:1118-23. 10. Lu Y, Penrod JR, Sood N, Woodby S, Philipson T. Dynamic cost-effectiveness of oncology drugs. The American journal of managed care 2012;18:S249-56. 11. Aggarwal S. Targeted cancer therapies. Nature reviews Drug discovery 2010;9:427-8. 12. Carr DR, Anastasaki E, Chriv E, Bradshaw SE. What Lifecycle Management Lessons Can We Learn From Pd-1 Immuno-Oncology Therapies? Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2015;18:A488. 13. Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. Mayo Clinic Proceedings 2012;87:935-43. 14. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439-42. 15. Grabner M, Johnson W, Abdulhalim AM, Kuznik A, Mullins CD. The value of atorvastatin over the product life cycle in the United States. Clinical therapeutics 2011;33:1433-43. 16. Ben-Aharon O, Shavit O, Magnezi R. Does drug price-regulation affect healthcare expenditures? The European Journal of Health Economics 2016:1-9. 17. QuintilesIMS Institute. Healthcare Informatics (2017), medicines use and spending in the U.S. A review of 2016 and outlook to 2021 in the United States. (Accessed May 17, 2017, at http://www.imshealth.com/en/thought-leadership/quintilesims-institute/reports/medicines-use-and-spending-in-the-us-review-of-2016-outlook-to-2021.) 18. 政策研究指標資料庫. 國際醫藥支出之比較. (Accessed August 08, 2017, at https://pride.stpi.narl.org.tw/.) 19. Mousnad MA, Shafie AA, Ibrahim MI. Systematic review of factors affecting pharmaceutical expenditures. Health policy (Amsterdam, Netherlands) 2014;116:137-46. 20. Joanne L, Leslie F, Brixner DI. Trends in Pharmaceutical Expenditures: The Impact on Drug Benefit Design. American Health & Drug Benefits 2008;1:29-34. 21. Dubois RW, Chawla AJ, Neslusan CA, Smith MW, Wade S. Explaining drug spending trends: does perception match reality? Health affairs (Project Hope) 2000;19:231-9. 22. Berndt ER. Pharmaceuticals in U.S. health care: determinants of quantity and price. The journal of economic perspectives : a journal of the American Economic Association 2002;16:45-66. 23. Morgan SG. Quantifying components of drug expenditure inflation: the British Columbia seniors' drug benefit plan. Health services research 2002;37:1243-66. 24. Addis A, Magrini N. New approaches to analysing prescription data and to transfer pharmacoepidemiological and evidence-based reports to prescribers. Pharmacoepidemiology and drug safety 2002;11:721-6. 25. Bae G, Park C, Lee H, Han E, Kim DS, Jang S. Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea. BMC health services research 2014;14:100. 26. Kwon HY, Hong JM, Godman B, Yang BM. Price cuts and drug spending in South Korea: the case of antihyperlipidemic agents. Health policy (Amsterdam, Netherlands) 2013;112:217-26. 27. Vandoros S. Therapeutic substitution post-patent expiry: the cases of ACE inhibitors and proton pump inhibitors. Health economics 2014;23:621-30. 28. Hsiao FY, Tsai YW, Huang WF. Price regulation, new entry, and information shock on pharmaceutical market in Taiwan: a nationwide data-based study from 2001 to 2004. BMC health services research 2010;10:218. 29. Jonsson B, Hofmarcher T, Lindgren P, Wilking N. The cost and burden of cancer in the European Union 1995-2014. European journal of cancer (Oxford, England : 1990) 2016;66:162-70. 30. Karikios DJ, Schofield D, Salkeld G, Mann KP, Trotman J, Stockler MR. Rising cost of anticancer drugs in Australia. Internal medicine journal 2014;44:458-63. 31. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. The New England journal of medicine 2009;360:626-33. 32. Express Scripts. The 2016 drug trend report highlights. (Accessed June 17, 2017, at http://lab.express-scripts.com/lab/drug-trend-report.) 33. 衛生福利部中央健康保險署. 衛生福利部中央健康保險署電子報. 健保引進標靶藥物,嘉惠癌症病患. (Accessed May 17, 2017, at https://www.nhi.gov.tw/epaperN/ItemDetail.aspx?DataID=4528&IsWebData=0&ItemTypeID=3&PapersID=409&PicID=.) 34. Hoadley J. Cost containment strategies for prescription drugs: assessing the evidence in the literature. Henry J Kaiser Family Foundation 2005. 35. Claxton K. OFT, VBP: QED? Health economics 2007;16:545-58. 36. Adamski J, Godman B, Ofierska-Sujkowska G, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC health services research 2010;10:153. 37. Vitry A, Roughead E. Managed entry agreements for pharmaceuticals in Australia. Health policy (Amsterdam, Netherlands) 2014;117:345-52. 38. Hsu JC, Lu CY. The evolution of Taiwan's National Health Insurance drug reimbursement scheme. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 2015;23:15. 39. 陳昭姿. 歷年健保新藥管理趨勢回顧. 醫療爭議審議報導 2014. 40. Yoo KB, Lee SG, Park S, et al. Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea. BMJ open 2015;5:e006940. 41. Hsu JC, Lu CY, Wagner AK, Chan KA, Lai MS, Ross-Degnan D. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study. Health policy (Amsterdam, Netherlands) 2014;116:196-205. 42. 衛生福利部食品藥物管理署. 西藥、醫療器材、含藥化粧品許可證查詢. (Accessed December 25, 2016, at https://www.fda.gov.tw/mlms/H0001.aspx.) 43. 衛生福利部中央健康保險署. 健保用藥品項網路查詢服務. (Accessed December 25, 2016, at http://www.nhi.gov.tw/query/query1.aspx.) 44. 衛生福利部. 衛生福利法規檢索系統. (Accessed December 25, 2016, at http://mohwlaw.mohw.gov.tw/.) 45. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. Journal of clinical pharmacy and therapeutics 2002;27:299-309. 46. Goss TF PE, Tarab A Recognizing Value in Oncology Innovation.White Paper: Pharmaceutical Research and Manufacturers of America (PhRMA). http://bostonhealthcarecom/resources/publications-2/ 2012, June. 47. Shih YR, Wang CY, Wen YC, Chen YH, Lin FJ, Hsiao FY. Reimbursement lag of innovative new drugs under Taiwan’s National Health Insurance system. ISPOR 22nd Annual International Meeting 2017. 48. 衛生福利部國民健康署. 103年癌症登記年報. (Accessed May 17, 2016, at https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=7330.) 49. American Society of Clinical Oncology. Utilization management in oncology. (Accessed May 21, 2017, at https://am.asco.org/utilization-management-oncology.) 50. Applied Clinical Trials. Competitive pressure for first-in-class drugs is intensifying. (Accessed May 26, 2017, at http://www.appliedclinicaltrialsonline.com/competitive-pressure-first-class-drugs-intensifying.) 51. Cheng N, Banerjee T, Qian J, Hansen RA. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011. Journal of the American Pharmacists Association 2017;57:341-8. 52. 羅義程. 台灣晚期腎細胞癌病患使用Sunitinib之處方型態分析: 成功大學; 2016. 53. Komen J, Forslund T, Hjemdahl P, Andersen M, Wettermark B. Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. British journal of clinical pharmacology 2017;83:642-52. 54. Taiwan Urological Association. Pocket guidelines 2016 edition. (Accessed March 12, 2017, at http://www.tua.org.tw/tua/index.php/tw/.) 55. Muglia VF, Prando A. Renal cell carcinoma: histological classification and correlation with imaging findings. Radiologia brasileira 2015;48:166-74. 56. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. The American journal of surgical pathology 2003;27:612-24. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67019 | - |
dc.description.abstract | 研究背景:近年來全球藥品支出持續攀升,而癌症藥品的支出成長更為顯著。綜觀過去文獻,認為藥品支出上升的主因為新藥的引進與藥品使用量的改變。然而,目前的研究多聚焦於新藥納入給付的當下,忽略了藥品納入給付後的一連串動態變化對藥品使用量的影響,包括與藥品自身相關的內在因素改變(如:藥品給付規定變更)以及與外部環境有關的外在因素介入(如:藥品競爭)。特別是癌症創新新藥,其內在和外在因素的變動極為顯著,但相關的實證資料仍然有限,無法提供癌症創新新藥納入健保後的全面性評估。
研究目的:於台灣全民健康保險系統下,檢視癌症創新新藥之給付時程並探討藥品給付規定變更和藥品競爭與藥品使用量之關聯性。 研究方法:本研究為一回溯性長期追蹤研究,以我國全民健康保險於2007至2013年間收載之癌症創新新藥為研究藥品。在給付時程分析部分,利用公開可取得之官方資料蒐集給付時程相關參數並進行描述性分析。在藥品使用量的分析部分,採用間斷區間時間序列設計,利用台灣全人口之衛生福利資料檔以及癌症登記年報檔取得2009至2014年之每月藥品使用量資料,以推論性統計的方式,分別探討介入因子─藥品使用規定變更以及藥品競爭,對藥品使用量之影響,並以level/trend change表示之。最後,合併兩大介入因子,綜合探討其與藥品使用量之關聯性。 研究結果:符合本研究之癌症創新新藥共計15項,包含14種治療領域,其中最多為治療晚期腎細胞癌之藥品。在給付時程分析部分,癌症創新新藥之健保給付時程(從取得我國藥品許可證至健保給付生效日)中位數為476天(平均值:606.6,標準差:299.0)。其中,曾歷經藥品給付規定變更有10項藥品,自健保給付生效日至藥品給付規定第一次變更,其時程中位數為548天(平均值:551,標準差:416.9)。曾新增適應症有9項藥品,自健保給付生效日至第一次新增適應症之時程中位數為853天(平均值:893.1,標準差:566.9)。而有4項藥品曾變更治療地位,自健保給付生效日至第一次治療地位變更之時程中位數為806天(平均值:1,020.0,標準差:664.9)。 在探討藥品給付規定變更與藥品使用量之關聯性部分,綜合分析10項藥品共計23項藥品給付規定變更的結果顯示,藥品給付規定變更類型中以新增適應症(34.8%)和使用限制變更(34.8%)最多,其次為治療地位變更(17.4%),而多種類型者最少(13.0%)。其中,新增適應症對於藥品使用量的level/trend change影響較顯著,而使用限制變更對藥品使用量的影響最不顯著。 在探討競爭藥品與藥品使用量之關聯性部分,本研究以晚期腎細胞癌作為標的治療領域。於該治療領域中,創新新藥的藥品使用量明顯高於舊有藥品;而創新新藥中又以sunitinib用量最多,temsirolimus用量最少。綜合分析該藥品市場的觀察結果,屬於first competition的競爭關係有3項,其中有2項皆對藥品使用量之level/trend change有顯著的影響。而屬於non-first competition的競爭關係有7項,其中4項對藥品使用量之level/trend change亦有顯著的影響。 最後,針對研究藥品sorafenib,綜合分析藥品使用規定變更以及藥品競爭對其使用量的影響。Sorafenib之藥品給付規定變更對其使用量沒有顯著影響;而屬於first competitor的sunitinib和pazopanib納入健保,則分別使sorafenib使用量之trend change和level change顯著下降。 研究結論:癌症創新新藥納入健保給付後,藥品給付規定變更與藥品競爭之變動極為顯著。在藥品給付規定變更中,以新增適應症對藥品使用量的影響最為顯著。而晚期腎細胞癌領域之藥品競爭無論為first-competition或為non-first competition皆顯著影響藥品使用量。藥品使用情形之評估,建議應以藥品生命週期的長期觀點,並且同時考量藥品給付規定變更以及藥品競爭的變動,以提供更全面、更完整的評估。 | zh_TW |
dc.description.abstract | Background: Pharmaceutical expenditures, particularly spending on innovative oncology drugs, are increasing dramatically. This rapid growth was largely driven by increasing utilization and the entry of innovative new drugs, as shown in previous studies. Nevertheless, existing studies are mainly limited to the analyses at the time of reimbursement of new drug without taking into account the dynamic changes resulted from numerous endogenous (such as the expansion of indications) and exogenous factors (such as drug competitions) after the reimbursement of new drug.
Objectives: To fill the current knowledge gap, the aims of this study were to investigate the listing time of innovative oncology drugs and to evaluate the effects of endogenous factors (reimbursement criteria changed) and exogenous factors (drug competitions) on utilization of innovative oncology drugs at and after the time of reimbursement under National Health Insurance (NHI) System in Taiwan. Methods: This is a retrospective longitudinal study covering 15 innovative oncology drugs reimbursed by the NHI between 2007 and 2013. Data sources for the timing of reimbursement were retrieved from publicly-available data. Monthly data (January 2009 to December 2014) of the consumption (volume) of studied drugs were obtained from National Health Insurance Research Database (NHIRD). Descriptive analyses were used to examine the listing time of innovative oncology drugs and interrupted time series analyses were used to evaluate the effects of reimbursement criteria changed and drug competition on utilization of innovative oncology drugs. Results: Among 15 innovative oncology drugs, there were 10 drugs with reimbursement criteria changed. We found that the average time from marketing authorization to reimbursement was 607 days (median: 476, SD: 299.0) and the time from reimbursement to first reimbursement criteria changed was 551 days (median: 548, SD: 416.9). The average time from reimbursement to first indication expansion and to line of therapy changed were 893 days (median: 853, SD: 566.9) and 1,020 days (median: 806, SD: 665), respectively. For endogenous factors (reimbursement criteria changed), segmented regression analyses showed statistically significant level or trend change of drug volume after indication expansion. However, there was no significant change in drug volume after restriction changed. For exogenous factors (drug competition), we found that both first competition and non-first competition were significantly associated with level or trend change of drug volume. Taking sorafenib as an example to examine both the impacts of endogenous and exogenous factor on drug volume after reimbursement, we found that the drug volume was not significantly changed after line of therapy changed (endogenous). However, the reimbursement of first competitors were significantly associated with a lower level or trend change of volume sorafenib consumed. Conclusions: In Taiwan, after drug reimbursement, the utilization of innovative oncology drugs changed dramatically. This was largely driven by indication expansion and new drug competition. Our findings suggest that drug utilization evaluation should take into account both endogenous and exogenous factors. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T01:17:25Z (GMT). No. of bitstreams: 1 ntu-106-R04451005-1.pdf: 4051791 bytes, checksum: d586700fdd45dd7aefb3a723c61400e2 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 致謝 i
中文摘要 ii Abstract v 目錄 viii 圖目錄 xii 表目錄 xiii 第一章 緒論 1 第一節 研究背景與重要性 1 第二節 研究目的 3 第二章 文獻回顧 4 第一節 藥品支出之現況 4 第二節 解構藥品支出上升原因 5 2.2.1 國外相關研究 5 2.2.2 國內相關研究 7 第三節 癌症藥品支出之現況 8 2.3.1 全球癌症藥品支出攀升 8 2.3.2 癌症藥品支出上升的原因 9 2.3.3 我國關於癌症藥品支出的探討 10 第四節 影響藥品支出或藥品使用之藥事政策 11 2.4.1 全球影響藥品支出或藥品使用之相關藥事政策 11 2.4.2 我國影響藥品支出或藥品使用之相關藥事政策 12 2.4.3 影響藥品支出或藥品使用之實證研究 15 第五節 以藥品生命週期為觀點探討藥品價值 16 第三章 研究方法 19 第一節 研究流程 19 3.1.1 研究對象 20 3.1.2 研究期間 22 3.1.3 介入因子之定義 22 第二節 研究材料 24 3.2.1 健保用藥品項查詢檔 24 3.2.2 衛生福利部中央健康保險署、衛生福利部食品藥物管理署公開資訊 24 3.2.3 衛生福利資料檔 24 第三節 研究藥品基本特性 25 第四節 各部分研究方法 27 第五節 第一部分 給付時程分析 29 3.5.1 研究設計 29 3.5.2 研究藥品 29 3.5.3 研究變項 30 3.5.4 資料處理流程 30 3.5.5 統計分析 30 第六節 第二部分 藥品給付規定變更與藥品使用量之關聯性 31 3.6.1 研究假說與研究架構 31 3.6.2 研究設計 31 3.6.3 研究藥品 32 3.6.4 研究變項 33 3.6.5 資料處理流程 33 3.6.6 統計分析 34 第七節 第三部分 藥品競爭與藥品使用量之關聯性 38 3.7.1 研究假說與研究架構 38 3.7.2 研究設計 38 3.7.3 研究藥品 40 3.7.4 研究變項 45 3.7.5 資料處理流程 46 3.7.6 統計分析 50 第八節 第四部分 綜合探討藥品給付規定變更及藥品競爭對藥品使用量之影響 53 3.8.1 研究假說與研究架構 53 3.8.2 研究設計 53 3.8.3 研究藥品 55 3.8.4 研究變項 55 3.8.5 資料處理流程 56 3.8.6 統計分析 56 第四章 研究結果 57 第一節 研究藥品基本特性 57 第二節 第一部分 給付時程分析 60 4.2.1 歷次新增適應症之時程 61 4.2.2 歷次治療地位變更之時程 61 第三節 第二部分 藥品給付規定變更與藥品使用量之關聯性 65 4.3.1 總論 65 4.3.2 藥品個論 67 第四節 第三部分 藥品競爭與藥品使用量之關聯性 85 4.4.1 晚期腎細胞癌之藥品市場 85 4.4.2 晚期腎細胞癌藥品市場各藥品使用量消長之趨勢 85 4.4.3 競爭藥品與藥品使用量之關聯性—區間迴歸分析 87 第五節 第四部分 綜合探討藥品給付規定變更及藥品競爭對藥品使用量之影響 98 第五章 討論 101 第一節 研究藥品基本特性 101 第二節 第一部分 給付時程分析 102 第三節 第二部分 藥品給付規定變更與藥品使用量之關聯性 103 第四節 第三部分 藥品競爭與藥品使用量之關聯性 106 第五節 第四部分 綜合探討藥品給付規定變更及藥品競爭對藥品使用量之影響 108 第六章 研究優勢與限制 110 第一節 研究優勢 110 第二節 研究限制 111 6.2.1 研究對象 111 6.2.2 研究材料 113 6.2.3 資料處理流程 113 6.2.4 統計分析 114 第七章 結論與建議 115 第八章 參考文獻 116 | |
dc.language.iso | zh-TW | |
dc.title | 全民健保體制下癌症創新新藥給付時程與使用量之評估 | zh_TW |
dc.title | Dynamic Evaluation of Listing Time and Utilization of Innovative Oncology Drugs under National Health Insurance System in Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蒲若芳,許銘能,柯博升,黃兆杰 | |
dc.subject.keyword | 癌症藥品,藥品使用,給付時程,藥品給付規定,藥品競爭, | zh_TW |
dc.subject.keyword | oncology drugs,drug utilization,listing time,reimbursement criteria,drug competition, | en |
dc.relation.page | 122 | |
dc.identifier.doi | 10.6342/NTU201703110 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-08-14 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 3.96 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。